DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation Meeting Abstract
| Authors: | Niazi, T.; McBride, S. M.; Williams, S.; Davis, I. D.; Stockler, M. R.; Martin, A. J.; Bracken, K.; Roncolato, F.; Horvath, L.; Sengupta, S.; Martin, J.; Lim, T.; Hughes, S.; McDermott, R. S.; Catto, J. W. F.; Kelly, P. J.; Parulekar, W. R.; Morgan, S. C.; Rendon, R. A.; Sweeney, C.; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) |
| Abstract Title: | DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304984 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS5103 |
| Notes: | Meeting Abstract: TPS5103 -- Meeting also held virtually -- Source: Wos |
